Abstract | BACKGROUND: OBJECTIVE: We sought to evaluate the immunologic and remodeling effects of budesonide transnasal nebulization in patients with eosinophilic CRSwNP. METHODS: Sixty patients with eosinophilic CRSwNP were randomized to receive budesonide or placebo treatment for 14 days by means of transnasal nebulization in a double-blind manner. Endoscopic polyp size scores (maximum = 6 points, Kennedy score) and visual analog scale scores for nasal symptoms were assessed before and after treatment. Similarly, polyp samples were evaluated for inflammatory cytokines, matrix metalloproteinases ( MMPs), and tissue inhibitors of metalloproteinases (TIMPs) by using an immunoassay; collagen by using histochemistry; eosinophils by using hematoxylin and eosin stain; and T-cell subsets by using flow cytometry. RESULTS:
Budesonide transnasal nebulization significantly reduced polyp size compared with placebo (mean difference between groups, -0.73 units; 95% CI, -1.15 to -0.32 units; P = .002) and improved symptoms. Polyp IL-5 and eotaxin expression decreased significantly, whereas TGF-β and IL-10 expression increased. Expression of IFN-γ and IL-17 was not altered. Budesonide transnasal nebulization consistently reduced eosinophil infiltration and TH2 cell frequency and increased natural regulatory T-cell and type 1 regulatory T-cell frequencies. Indices of remodeling, including albumin, MMP-2, MMP-7, MMP-8, and MMP-9, were significantly decreased, whereas collagen deposition and TIMP-1, TIMP-2, and TIMP-4 levels were significantly increased. Budesonide transnasal nebulization did not suppress the hypothalamic-pituitary-adrenal axis or cause any serious side effects. CONCLUSION: Short-term budesonide transnasal nebulization is an effective and safe treatment option in patients with eosinophilic CRSwNP, achieving clinical improvement by regulating remodeling, cytokine expression, and T-cell subset distribution.
|
Authors | Chengshuo Wang, Hongfei Lou, Xiangdong Wang, Yang Wang, Erzhong Fan, Ying Li, Hong Wang, Claus Bachert, Luo Zhang |
Journal | The Journal of allergy and clinical immunology
(J Allergy Clin Immunol)
Vol. 135
Issue 4
Pg. 922-929.e6
(Apr 2015)
ISSN: 1097-6825 [Electronic] United States |
PMID | 25483598
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Bronchodilator Agents
- Cytokines
- Inflammation Mediators
- Budesonide
|
Topics |
- Adult
- Aged
- Bronchodilator Agents
(administration & dosage, adverse effects)
- Budesonide
(administration & dosage, adverse effects)
- Chronic Disease
- Cytokines
(metabolism)
- Eosinophils
(pathology)
- Female
- Humans
- Inflammation Mediators
(metabolism)
- Male
- Middle Aged
- Nasal Polyps
(complications)
- Nebulizers and Vaporizers
- Rhinitis
(complications, diagnosis, drug therapy)
- Sinusitis
(complications, diagnosis, drug therapy)
- Treatment Outcome
- Young Adult
|